Pricing Log in Create free account

Altimmune, Inc. (ALT) vs Relmada Therapeutics, Inc. (RLMD)

Altimmune, Inc. and Relmada Therapeutics, Inc. are both Biotechnology companies. Relmada Therapeutics, Inc. is the larger, with a market value of $455.5M against $396.8M — 1.1× the size. Across the 11 metrics below, Relmada Therapeutics, Inc. leads on 6 and Altimmune, Inc. on 5.

Valuation

Metric ALT RLMD Biotechnology median
P/E n/m n/m 10.64
P/S 8,224.03 n/m 9.59
P/B 0.80 2.32 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales 1,889.09 n/m 9.45
Earnings yield (38.24%) (22.37%) (34.69%)
Free cash flow yield (20.29%) (26.54%) (24.02%)

Profitability

Metric ALT RLMD Biotechnology median
Gross margin 100.00% 0.00% 65.59%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (28.87%) (55.66%) (51.96%)
Return on assets (25.58%) (51.57%) (46.06%)
Return on invested capital (34.30%) 0.00% 0.00%

Growth

Metric ALT RLMD Biotechnology median
Revenue growth (TTM) 130.00% — 4.59%
EPS growth (last fiscal year) 25.37% 45.28% 29.88%
Revenue growth, 5-year CAGR (65.33%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALT RLMD Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 26.78 29.52 4.86
Net debt to EBITDA 2.49 1.57 1.01

Dividend

Metric ALT RLMD Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric ALT RLMD Biotechnology median
Market cap 396.82m 455.48m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack